SEC Form 4 · accession 0001104659-17-040238
Nabriva Therapeutics plc · NBRV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
George Harrison Talbot
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 6:14 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001641640
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Jun 15, 2017 | S | 100 | $94.10 | D | 3,249 | D | |
| Common SharesF1,F3 | Jun 16, 2017 | S | 24 | $93.50 | D | 3,225 | D | |
| Common SharesF1,F4 | Jun 19, 2017 | S | 46 | $91.00 | D | 3,179 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The common shares whose sale is reported on this line are represented by American Depositary Shares ("ADSs"). Each ADS represents one tenth (1/10) of a common share of Nabriva Therapeutics AG. The reporting person may hold both common shares and ADSs representing common shares, and Column 5 reports such holdings on an aggregate basis in terms of the corresponding number of common shares.
- F2The price of $94.10 per common share was derived from the sale price on June 15, 2017, of $9.41 per ADS, multiplied by ten.
- F3The price of $93.50 per common share was derived from the sale price on June 16, 2017, of $9.35 per ADS, multiplied by ten.
- F4The price of $91.00 per common share was derived from the sale price on June 19, 2017, of $9.10 per ADS, multiplied by ten.